Clinical trials: Complication in Systemic Lupus Erythematosus
Lupus Nephritis
A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients
The purpose of this study is to compare the efficacy and safety of tacrolimus capsules with leflunomide tablets in the treatment of lupus nephritis.
- Trial name
- NCT01342016
- Testing
- tacrolimus capsule, leflunomide tablet, prednisone
- Where
- 12 sites in China
- Volunteers
- 84 people
- Sponsor
- Astellas Pharma Inc
Lupus Nephritis
Rituximab Combining With Low-Dose Mycophenolate Mofetil on Proliferative Lupus Nephritis in Children
The objective of this study is to assess the efficacy and safety of rituximab combining with low-dose mycophenolate mofetil in the induction therapy of proliferative lupus nephritis in children.
- Trial name
- NCT07675291
- Testing
- rituximab, Mycophenolate Mofetil (MMF) Treatment, Cyclophosphamide
- Volunteers
- 112 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Lupus Nephritis
Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil
The sponsor electively terminated the study because the risk mitigation measures, deemed necessary after an unforeseen safety event, could not be effectively implemented within this protocol while maintaining study timelines…
- Trial name
- NCT01369628
- Testing
- Atacicept
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- EMD Serono
Nephritis, Lupus, Lupus Erythematosus, Systemic
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
The goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis.
- Trial name
- LUMIOS (NCT07201129)
- Testing
- Cenerimod
- Where
- 14 sites in United States
- Volunteers
- 300 people
- Sponsor
- Viatris Innovation GmbH
Systemic Lupus Erythematosus
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
Primary objective: Safety and tolerability of NKX019, administered after lymphodepletion (LD). Secondary objectives: Assess clinical activity of NKX019 in subjects with systemic lupus erythematosus (SLE) with or without active…
- Trial name
- NCT06518668
- Testing
- NKX019, Cyclophosphamide LD
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Hospital for Special Surgery, New York
Refractory Lupus Nephritis, Refractory Systemic Sclerosis
A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)
The main aim of the trial is to learn how well adults with refractory lupus nephritis (LN) or refractory systemic sclerosis (SSc) tolerate TAK-007 and to check for side effects (adverse events).
- Trial name
- NCT06377228
- Testing
- TAK-007, Chemotherapy Agents
- Where
- United States
- Sponsor
- Takeda
Lupus Nephritis, Primary Membranous Nephropathy
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in…
- Trial name
- NCT06557265
- Testing
- NKX019, Fludarabine, Cyclophosphamide
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 120 people
- Sponsor
- Nkarta, Inc.
Lupus Nephritis
Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis
This study will be conducted to find out whether low dose or high dose cyclophosphamide therapy is effective in the treatment of proliferative lupus nephritis.It will also compare the side effects and risks of infection in low…
- Trial name
- NCT02645565
- Testing
- Cyclophosphamide, Azathioprine, Methylprednisolone
- Where
- India
- Volunteers
- 75 people
- Sponsor
- Jawaharlal Institute of Postgraduate Medical Education & Research
Lupus Nephritis
An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis
The main objectives of this trial are to evaluate the long term efficacy and safety of different doses of BI 655064 versus placebo as add-on therapy to Standard of Care (SOC) during maintenance therapy for lupus nephritis.
- Trial name
- NCT03385564
- Testing
- BI 655064
- Where
- 36 sites in United States, Australia and 14 more
- Volunteers
- 69 people
- Sponsor
- Boehringer Ingelheim
Learning
Application of the AI Platform iLN Based on DeepSeek in the Teaching of Lupus Nephritis
Aim: To evaluate the application effect of the teaching platform iLN in the teaching of lupus nephritis, aiming to provide practical experience and evidence-based support for the implementation of generative AI technology in…
- Trial name
- NCT07706998
- Testing
- An iLN interactive teaching platform, PPT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Nanjing University
Lupus Nephritis
Fibroblast Activating Protein Inhibitor PET Imaging in Lupus Nephritis
Abnormal high expression of fibroblast activating protein (FAP) has been found in inflammatory reactions and benign fibrosis tissue.
- Trial name
- NCT05845151
- Testing
- 68Ga-FAPI-04 PET
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Proteinuria
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
The primary objective of this study is to assess the impact of proteinuria on the pharmacokinetic (PK) of a single dose of ALXN1720 in participants with proteinuria.
- Trial name
- NCT05314231
- Testing
- ALXN1720
- Where
- 2 sites in South Korea
- Volunteers
- 13 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Lupus Erythematosus, Systemic, Lupus Glomerulonephritis
Mesenchymal Stromal Cells (MSC´s) in Renal Lupus
Phase II Clinical Trial to Assess the dose-response and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells (MSCs) in Severe Renal Systemic Lupus Erythematosus (SLE).
- Trial name
- MSC-ROLE (NCT03917797)
- Testing
- MSC treatment, Standard of Care
- Where
- 2 sites in Chile
- Volunteers
- 39 people
- Sponsor
- Universidad de los Andes, Chile
Systemic Lupus Erythematosus
Study of LJP 394 (Abetimus Sodium) in Lupus Patients
The primary purpose of this study is to assess the safety and pharmacodynamic effect of LJP 394 at doses of 100 mg, 300 mg and 900 mg on anti-dsDNA antibody levels in patients with SLE.
- Trial name
- NCT00390091
- Testing
- abetimus sodium (LJP 394)
- Where
- 2 sites in United States
- Sponsor
- La Jolla Pharmaceutical Company
Lupus Nephritis
Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)?
Introduction and background : Glomerulonephritis and auto-immune diseases are often associated. Lupus nephritis (LN) is one of the major clinical manifestations of systemic lupus erythematosus (SLE) which have a severe impact on…
- Trial name
- GOODLUPUS (NCT03664908)
- Testing
- Detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method).
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Lupus Nephritis
Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V)
This is an open, prospective study to assess the efficacy and safety of Tacrolimus (FK506) combined with MMF in the treatment of class III, IV, V + IV or V + III lupus nephritis.
- Trial name
- NCT00298506
- Testing
- Multitherapy
- Where
- 2 sites in China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Nanjing University School of Medicine
SLE Glomerulonephritis Syndrome, WHO Class V
ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis
This is an open-label, randomized, multi-center, Phase IV study of Acthar Gel in patients with biopsy-proven membranous (Class V) lupus nephritis (LN) aimed at providing proof-of-concept data that Acthar is a safe and effective…
- Trial name
- NCT01926054
- Testing
- Acthar gel
- Where
- United States
- Sponsor
- Ohio State University
Lupus Nephritis, Immunoglobulin A Nephropathy
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis …
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- RUBY-3 (NCT05732402)
- Testing
- Povetacicept
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 72 people
- Sponsor
- Alpine Immune Sciences, Inc.
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Sjogren's Syndrome (SS), Inflammatory Myopathy
- Trial name
- NCT07123519
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Lupus Nephritis
Comparison between2 Drugs in Lupus Nephritis
The aim of this work is to study the effect and side effects of the cyclophosphamide versus mycophenolate in lupus nephritis
- Trial name
- NCT04424602
- Testing
- cyclo phosphamide, mycophenolate
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Al-Azhar University